Analysing circulating tumour cells with epithelial and mesenchymal features for prostate cancer prognosis
Lixia Xu, Yiping Lu(University of Hong Kong - Shenzhen Hospital), Y. Wang, Greg Shaw(University College Hospital), Tianyu Guo(Electric Power Research Institute), Xueying Mao(Ministry of Education), Amar Ahmad(Cancer Research UK), Daniel M. Berney(Queen Mary University of London), R.T.D. Oliver(University of Cambridge), Pui Ying Chan(Barts Health NHS Trust), Jeffrey F. Hines, J. Shamash
Cited by 0
Related Papers
Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study
|The Lancet Oncology|2020|631
Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial
|The Lancet|2005|447
Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.
|Journal of Clinical Oncology|1997|334
Cancer incidence in the United Kingdom: projections to the year 2030
|British Journal of Cancer|2011|285
Trends in the lifetime risk of developing cancer in Great Britain: comparison of risk for those born from 1930 to 1960
|British Journal of Cancer|2015|275